#United States #Houston #Mallinckrodt #CKD #Terlipressin

Mallinckrodt's Insights on Terlipressin Presentation at Kidney Week 2025

Mallinckrodt plc, a prominent global specialty pharmaceutical firm, is set to present compelling research at Kidney Week 2025, scheduled from November 5-9, 2025, in Houston, Texas. This year's event will feature two significant poster presentations focused on the use of terlipressin in treating patients with hepatorenal syndrome-acute kidney injury (HRS-AKI).

Overview of Terlipressin and Hepatorenal Syndrome

Terlipressin, marketed as TERLIVAZ®, has garnered attention as the first FDA-approved treatment for enhancing kidney function in adults suffering from HRS with rapid kidney function deterioration. HRS is an infrequent but critical condition affecting more than 60,000 Americans annually and is characterized by its high mortality rate if left untreated. Mallinckrodt aims to highlight essential research regarding the management of this severe condition, particularly the role of terlipressin in patient outcomes.

Key Research Findings

One of the presentations, identified as Poster #FR-PO0122, will delve into the Association of Paracentesis with HRS Reversal, deriving insights from the CONFIRM Trial of Terlipressin. The session, led by Dr. Juan Carlos Q. Velez, will occur on November 7, 2025. This analysis focuses on how paracentesis, a procedure that alleviates intra-abdominal pressure, may positively affect renal hemodynamics in patients treated with terlipressin.

In contrast, Poster #SA-PO1188, presented by Dr. Xingyue Huang, will investigate the Impact of Chronic Kidney Disease (CKD) on Treatment Outcomes in individuals with HRS-AKI treated with terlipressin. This research analyzes real-world data to discern how pre-existing CKD may influence clinical responses for adults hospitalized with HRS-AKI, contributing to a broader understanding of patient management strategies.

Importance of the Data Presented

Dr. Christopher White, Senior Director and Hepatology Lead at Mallinckrodt, emphasizes the significance of these findings. He states, "The poster presentations at this year's ASN Annual Meeting aim to help expand our knowledge of the potential factors impacting appropriate HRS-AKI patients treated with TERLIVAZ, like pre-existing CKD or undergoing paracentesis. The more clinical data and real-world experience available, the better it supports our understanding of appropriate patients who are most likely to benefit from TERLIVAZ treatment."

The focus on both theoretical and real-world applications in these studies underscores Mallinckrodt's commitment to advancing kidney health and improving therapeutic approaches for HRS-AKI.

Conclusion

As the number of HRS hospitalizations continues to rise, the dissemination of knowledge and effective treatment strategies is paramount. Mallinckrodt's contributions at Kidney Week 2025 are poised to illuminate vital insights that could enhance the treatment landscape for those battling this challenging condition. Through these poster presentations, the company not only reaffirms its dedication to addressing unmet medical needs but also seeks to foster greater understanding of optimal approaches for patients with hepatorenal syndrome.

For additional information, please visit Mallinckrodt's official website.